Gilead's HIV PrEP Franchise Hits $1B+ Quarterly Sales, With Yeztugo Growth Tempered by Durability Concerns

on

Gilead's HIV PrEP franchise posted quarterly sales above $1 billion for the first time in Q2 2026, more than doubling year‑over‑year and now running at roughly a $4 billion annual pace.

Driving this were Descovy PrEP sales of about $801 million (up 60% YoY) and the long‑acting injectable Yeztugo, which notched $232 million in the quarter, up 40% sequentially and now guiding to about $1 billion in full‑year 2026 sales.

Analysts praised Yeztugo's strong early uptake and more than 70% persistency at six months, but question whether current growth is sustainable given dependence on patient switches from oral PrEP, pricing pressure, and the need for broader PrEP‑market adoption to justify multi‑billion‑dollar peak forecasts.

Sources:

Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...

Gilead Raised HIV Guidance on Its Q2 Earnings Call. ...

Gilead Sales Beat Expectations on Strong HIV Prevention ...

Gilead Q2 2026 slides: HIV, PrEP drive strongest growth in ...

Gilead Sciences Q2 Earnings Call Highlights

Gilead 2026 outlook short of Wall Street view, shares dip

Can Gilead Sciences HIV Franchise Drive Long-Term Growth?

Gilead Reports Strong HIV Growth, Raises Outlook for 2026

Gilead's 5.8% Rally Overshadows Weak 2026 Outlook, $1.77B ...

Gilead's Yeztugo Gets Early Stickiness, But Growth Looks Harder

Gilead sets blockbuster bar for Yeztugo's first full year on ...

GILD: Future Returns Will Depend On HIV Franchise And Oncology Execution

Gilead second-quarter sales rise 8%, beating Wall Street ...

Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch

Gilead earnings loom: Can Yeztugo, Trodelvy offset acquisition costs? By Investing.com